McCullough observes that, “We could have dramatically reduced COVID fatalities and hospitalizations using early treatment protocols and repurposed drugs including ivermectin and hydroxychloroquine and many, many others.”
Indeed. But there would have been far less profit made by Pfizer, et al, as those repurposed treatments would have blocked the Emergency Use Authorization for the vaccines.
